SOPHiA GENETICS (NASDAQ:SOPH) Sees Large Volume Increase – Here’s Why

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) saw unusually-strong trading volume on Tuesday . Approximately 286,789 shares changed hands during mid-day trading, an increase of 16% from the previous session’s volume of 246,722 shares.The stock last traded at $8.3490 and had previously closed at $8.40.

Analyst Upgrades and Downgrades

Several research firms have commented on SOPH. BTIG Research upped their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, HC Wainwright increased their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Stock Performance

The stock’s 50-day simple moving average is $6.70 and its 200-day simple moving average is $5.53. The stock has a market cap of $694.65 million, a price-to-earnings ratio of -7.20 and a beta of 0.98. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Analysts forecast that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Insider Activity

In related news, Chairman Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $7.61, for a total value of $64,685.00. Following the transaction, the chairman directly owned 3,444,322 shares of the company’s stock, valued at $26,211,290.42. This trade represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CTO Abhimanyu Verma sold 5,000 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $8.80, for a total value of $44,000.00. Following the sale, the chief technology officer owned 172,171 shares of the company’s stock, valued at $1,515,104.80. The trade was a 2.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 344,842 shares of company stock worth $2,199,315. 4.88% of the stock is owned by insiders.

Institutional Trading of SOPHiA GENETICS

Several institutional investors and hedge funds have recently modified their holdings of SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in SOPHiA GENETICS by 246.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares during the last quarter. Akre Capital Management LLC boosted its stake in shares of SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. AWM Investment Company Inc. acquired a new stake in shares of SOPHiA GENETICS in the 2nd quarter valued at approximately $9,809,000. Principal Financial Group Inc. grew its holdings in shares of SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Finally, Archon Capital Management LLC grew its holdings in shares of SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company’s stock valued at $2,061,000 after purchasing an additional 14,342 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.